Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12...910111213141516171819...2425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Cytomegalovirus Gastroenteritis in Patients with Acute Graft-Versus-Host Disease (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_5618;    
    We illustrated the adjusted cumulative incidence of NRM in patients with and without letermovir prophylaxis in Figure B. [Conclusion] To our knowledge, this is the largest study summarizing the characteristics and outcomes of cytomegalovirus gastroenteritis after acute GVHD. Our findings underscore the importance of more stringent surveillance with endoscopy and prevention with letermovir based on a comprehensive risk assessment.
  • ||||||||||  Orencia (abatacept) / BMS
    Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_5606;    
    However, a recent registry study showed increased incidence GvHD and inferior outcomes in patients receiving haploidentical SCT with PTCy, tacrolimus and mycophenolate mofetil for GvHD prevention as opposed to matched unrelated donor SCT with PTCy-based GvHD prevention...In early studies, abatacept has shown promising results when added to methotrexate and tacrolimus in matched and mismatched donor SCT...All patients received standard supportive care including levofloxacin until neutrophil engraftment, posaconazole until day +75, acyclovir for 1 year and, if CMV positive by serology, letermovir until day +100...One patient had EBV reactivation and required preemptive therapy with 2 weekly rituximab doses...The study is accruing actively and the results of a larger cohort with longer follow-up will be presented at the meeting. If confirmed, by improving the outcomes of haploidentical SCT, this regimen may further address a health care disparity issue, offering almost every patient in need of allogeneic SCT an alternative donor option with equal outcomes.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Promune (agatolimod) / Pfizer
    A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_4535;    
    P2
    Preemptive antiviral therapy is associated with drug-induced toxicities, and prophylactic therapy with letermovir is associated with late reactivations and delayed antiviral immune reconstitution...Our group has developed a peptide vaccine, CMVPepvax, composed of an HLA-A*0201 restricted pp65 495-503 CD8 T cell epitope, covalently linked to a universal tetanus T helper epitope and co-administered with PF-03512676 adjuvant...Early CMV reactivation/disease detected before receipt of the second vaccine may have reduced the ability of PepVax to elicit a protective T cell response. Transfer of vaccine-induced immunity through donor CMV immunization combined with recipient booster immunization may overcome this issue and lead to faster immune reconstitution post-HCT.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Cytomegalovirus and Epstein Barr Virus Reactivation after Allogeneic Stem Cell Transplantation in Pre- and Post-Letermovir Era (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_3368;    
    The pre-letermovir group (group A, n=230) included patients who had received prophylaxis with ciclosporine A (CSA) plus micophenolic acid (MFA) (N=17) or CSA plus short course methotrexate (MTX) (N=96) or CSA plus MFA plus Cy-post (n=117)...Sixty-eight of them received letermovir in addition to acyclovir as CMV prophylaxis...However, CMV infection rate was notably reduced by letermovir Introduction, while EBV infection rate not appeared to be affected by that. Figure 1: A) Day 100 cumulative incidence of CMV according to letermovir prophylaxis administration; B) One year cumulative incidence of CMV according to cyclophosphamide post transplant administration; C) One year cumulative incidence of EBV according to cyclophosphamide post transplant administration.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enrollment closed:  Letermovir Use in Heart Transplant Recipients (clinicaltrials.gov) -  Nov 2, 2021   
    P4,  N=35, Active, not recruiting, 
    One of the limitations in the LTV era is identifying the clinical scenarios surrounding the CMVi and CS-CMVi that may relate to compliance, absorption from gastrointestinal tract, and affordability or coverage of LTV after discharge from hospital. Not yet recruiting --> Active, not recruiting
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Letermovir for the Management of Cytomegalovirus-associated Uveitis. (Pubmed Central) -  Oct 31, 2021   
    Mean VA was 0.08 logMAR and IOP was 9 mmHg. Letermovir may be an alternative treatment for CMV-AU in patients with persistent inflammation or side effects on valganciclovir.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Review, Journal:  Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. (Pubmed Central) -  Oct 31, 2021   
    The limited availability of foscarnet, an alternative for patients who are not responsive to or cannot tolerate ganciclovir, is a crucial issue in Taiwan. For pediatric allo-HSCT recipients, more data are needed to propose a CMV management recommendation.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    [VIRTUAL] Cytomegalovirus (CMV) Retinitis during Maintenance Chemotherapy for Acute Lymphoblastic Leukemia () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1814;    
    Early identification of the disease is imperative as delay can result in blindness or further systemic CMV disease. Treatment is challenging, involving systemic and intravitreal antiviral therapy, serial ophthalmologic exams, serum CMV monitoring, and close coordination with the treating hematologist.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    Clinical, Review, Journal:  Prevention and therapy of viral infections in patients with solid organ transplantation. (Pubmed Central) -  Oct 1, 2021   
    This review offers an overview of the most relevant viral infections in the SOT population, with a focus on herpesviruses (cytomegalovirus, Epstein-Barr virus, varicella-zoster virus, and herpes simplex virus 1 and 2) and polyomaviruses (human BK polyomavirus). In addition, the currently recommended prophylactic and treatment approaches are summarized, as well as the new antiviral agents in different phases of clinical development.
  • ||||||||||  Tembexa (brincidofovir oral) / SymBio Pharma
    Journal:  A Eulogy for Dr. Francisco Miguel Marty Forero. (Pubmed Central) -  Sep 24, 2021   
    As some of those who were lucky enough to have been mentored by Dr. Francisco Marty in transplant infectious diseases, we stand with the larger medical community in mourning his untimely death and in commemorating him as a uniquely exceptional and talented physician, investigator, teacher, mentor, friend, artist, and human being.